TEVA, Sandoz and Dr. Reddy's are shifting toward complex generics and biosimilars to counter pricing pressure and strengthen ...

Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead ...

Glen Santangelo Barclays Bank PLC, Research Division. All right. Good morning, everybody. Why don't we get started for our first presentation? We're very excited to host Richard F ...

Xeris Biopharma benefits from the FDA's CRL to Corcept's relacorilant, removing a major competitive threat to Recorlev sales ...

Brookfield Corporation trades at a discount to its assets and holdings, and its value could continue to compound in the coming years. SSR Mining remains one of the best ways to capitalize on rising ...

Teva Pharmaceutical Industries (NYSE:TEVA) agreed a $400 million funding partnership with Blackstone Life Sciences to support ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Plus, the necessary guardrails around AI's role in content creation.

A $400 million, four-year Blackstone Life Sciences financing supports ongoing and future duvakitug development, with ...

Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA ...

Duvakitug is currently in phase 3 trials for ulcerative colitis and Crohn’s disease.

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today’s Pharmaceutical Executive Daily, ...